



Dedicated To Life

May 20, 2022

BSE Limited

Listing Department
P J Towers, Dalal Street,
Fort, Mumbai-400 001
Scrip Code: 532321

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, 5th floor, Plot No. – C/1, G
Block, Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
NSE Symbol: ZYDUSLIFE

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting – proposal for buyback of equity shares of Zydus Lifesciences Limited (“Company”).

In continuation of our letter dated May 17, 2022 and in terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“**Listing Regulations**”), we wish to inform you that the Board of Directors of the Company, at its meeting held today (i.e., May 20, 2022), has *inter-alia*:

1. approved the proposal to buyback of not exceeding 1,15,38,461 (One Crore Fifteen Lacs Thirty Eight Thousands Four Hundred Sixty One) fully paid-up equity shares of the Company, each having a face value of INR 1/- (“**Equity Shares**”), representing up to 1.13% of the total number of equity shares in the paid-up equity share capital of the Company, at a price of INR 650/- (Rupees Six Hundred and Fifty only) per Equity Share (“**Buyback Price**”) payable in cash for an aggregate amount not exceeding INR 750,00,00,000/- (Rupees Seven Hundred and Fifty Crores only) (“**Buyback Size**”) being 7% and 4% of the aggregate of the fully paid-up equity share capital and free reserves as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2022, respectively. The Buyback Size does not include transaction costs viz. brokerage costs, fees, turnover charges, applicable taxes such as buyback tax, securities transaction tax, goods and services tax, stamp duty, etc., expenses incurred or to be incurred for the buyback like filing fees payable to the Securities and Exchange Board of India (“**SEBI**”), advisors/ legal fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses, etc.

The buyback is proposed to be made from all of the equity shareholders/ beneficial owners of the Company, including the promoters of the Company (as defined under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011), who hold Equity Shares as of the record date, on a proportionate basis through the “tender offer” route as prescribed under the Buyback Regulations, using the “Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeovers, Buy Back and Delisting” notified by SEBI *vide* circular CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 read with SEBI circular CFD/DCR2/CIR/P/2016/131 dated December 9, 2016 and SEBI circular SEBI/HO/CFD/DCR-III/CIR/P/2021/615 dated August 13, 2021, including any

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : ‘Zydus Corporate Park’, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

amendments or statutory modifications for the time being in force, in accordance with the provisions contained in the Buyback Regulations and the Companies Act, 2013 and rules made thereunder.

2. in compliance with Regulation 42 of the Listing Regulations and Regulation 9(i) of the Buyback Regulations, fixed June 2, 2022 as the record date for the purposes of determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback.
3. approved the formation of a buyback committee ("**Buyback Committee**") and delegated its powers to the Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buyback.

The pre-buyback shareholding pattern as on May 13, 2022 is enclosed at **Annexure**. Please note that the details regarding the post-buyback shareholding pattern have not been provided since the actual number of Equity Shares that are bought back and category of shareholders from whom the Equity Shares will be bought back cannot be determined at this stage.

The public announcement setting out the process, timelines, and other requisite details will be released in due course in accordance with the Buyback Regulations.

We would like to inform you that the said meeting commenced at 12:10 p.m. and concluded at 1:10 p.m.

We request you to kindly take the above on record.

Thanking you.
Yours sincerely,

For Zydus Lifesciences Limited

Dhaval Soni
Company Secretary & Compliance Officer

Encl. As above



Annexure

Pre-buyback shareholding pattern of the Company as on May 13, 2022 is set out below:

Sr. No.	Shareholder Category	No. of shareholders	No. of Equity Shares	% shareholding
1.	Promoter and promoter group	8	76,65,34,434	74.88
2.	Mutual funds	29	5,52,08,388	5.39
3.	Alternative investment funds	5	2,39,727	0.02
4.	Foreign portfolio investor	126	2,62,72,784	2.56
5.	Financial institutions / banks	9	43,71,071	0.43
6.	Insurance companies	11	7,06,13,386	6.90
7.	Central/ State Governments	5	7,72,187	0.07
8.	Individuals (upto INR 2 lacs)	3,94,917	7,21,14,306	7.04
9.	Individuals (above INR 2 lacs)	10	84,60,980	0.83
10.	NBFCs registered with RBI	7	12,975	0.00
11.	Investor Education Protection Fund	1	14,08,541	0.14
12.	Trusts	22	19,10,712	0.19
13.	HUF	4,995	23,11,044	0.23
14.	NRIs (repat and non-repat)	7,204	37,64,411	0.37
15.	Bodies corporate/ clearing members	1,258	92,90,368	0.91
16.	LLPs, foreign nationals	106	4,57,286	0.05
Total		4,08,713	102,37,42,600	100

Note: The post buyback shareholding pattern of the Company shall be ascertained subsequently.

